Aldeyra Therapeutics, Inc.
Financials
Valuation Metrics
Aldeyra Therapeutics, Inc.'s Market Cap is $82M. At end of 2025 it was $312M. Ranked #3087 of 3,121 in US market (top 99%), #1433 of 1,463 on NASDAQ (top 98%), #264 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 99%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $82M | US#3,087/3,121 Sec#264/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-23M | US—/3,121 Sec—/266 |
| Total Assets | $48M | US#3,083/3,121 Sec#266/266 |
| Net Assets | $38M | US#2,878/3,121 Sec#229/266 |
| Employees | 7 | US#2,795/3,121 Sec#226/266 |
| Value | ||
| P/B | 2.17x | US#1,366/3,121 Sec#59/266 |
| FCF Yield | -26.87% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -60.85% | US#2,722/3,121 Sec#173/266 |
| ROA | -48.49% | US#2,983/3,121 Sec#209/266 |
| Financial Health | ||
| Debt Ratio | 25.49% | US#284/3,121 Sec#94/266 |
| Total Debt | $143447.00 | US#3,020/3,121 Sec#259/266 |
| FCF | $-22M | US#2,436/3,121 Sec#97/266 |
| Cash | $45M | US#2,618/3,121 Sec#234/266 |
| Current Ratio | 4.91x | US#484/3,121 Sec#148/266 |
| Performance | ||
| 1Y Return | -72.85% | US#3,077/3,121 Sec#262/266 |
| 1M Return | -13.92% | US#2,528/3,121 Sec#195/266 |
| From 52W High | -77.07% | US#3,059/3,121 Sec#254/266 |
| 1Y MDD | -78.40% | US#3,053/3,121 Sec#252/266 |
| Trading | ||
| Volume | 259,823 shares | US#2,215/3,121 Sec#227/266 |
| Trading Value | $355957.00 | US#3,066/3,121 Sec#260/266 |
| Per Share | ||
| EPS | $-0.38 | US—/3,121 Sec—/266 |
| BPS | $0.63 | US#2,745/3,121 Sec#215/266 |
Company Info
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.